Gate Bioscience

Gate Bioscience is a preclinical biotechnology company with the slogan “A new frontier of protein elimination”. The company is focused on creating a new class of medicines known as Molecular Gates, which are small molecule drugs designed to selectively eliminate harmful extracellular proteins at their origin within the cell. With over 4,000 distinct extracellular proteins produced by humans, of which more than 1,000 can drive diseases, Gate Bioscience aims to eliminate diseases by targeting these disease-causing proteins. Molecular Gates operate through a unique therapeutic mechanism. They bind to a single channel in the cell, effectively creating a “gate” that recognizes and blocks specific disease-causing proteins from exiting. This process leads to the degradation of the harmful protein by the cell instead of being secreted, thus preventing the progression of diseases. Founded in 2021 and headquartered in the United States, Gate Bioscience has attracted significant attention from renowned investors, including Versant Ventures, a16z Bio + Health (Andreessen Horowitz), ARCH Venture Partners, and GV. The company recently secured a $60.00M Series A investment on 01 November 2023, indicating strong support and confidence from the investment community in its innovative approach to combating diseases through protein elimination. For more information, visit www.gatebio.com. This promising company is poised to revolutionize the field of biotechnology with its groundbreaking Molecular Gate medicines.